Source link : https://www.newshealth.biz/health-news/mixed-signals-from-trials-of-perioperative-neoadjuvant-immunotherapy-for-early-tnbc/
SAN ANTONIO — Two trials of neoadjuvant immunotherapy for triple-negative breast cancer (TNBC) produced mixed efficacy signals. The NSABP B-59/GBG-96-GeparDouze trial showed that adding perioperative atezolizumab (Tecentriq) to neoadjuvant chemotherapy failed to improve event-free survival (EFS) despite a significant improvement in pathologic complete response (pCR). The China-based CamRelief trial also showed a significant improvement in […]
Author : News Health
Publish date : 2024-12-15 22:44:43
Copyright for syndicated content belongs to the linked Source.